ESPE Yearbook of Paediatric Endocrinology

ESPE Yearbook of Paediatric Endocrinology

ISSN 1662-4009 (online)

Published by BioScientifica

Page 15 of about 1557 results

ey0018.9 | Carla Bizzarri, Sara Ciccone, Stefania Pedicelli | ESPEYB18

9. Oncology and Chronic Disease

Bizzarri Carla , Ciccone Sara , Pedicelli Stefania

PrefaceAs in previous years, most of the selected papers concern the medium and long-term complications of cancer therapy. Issues related to long-term surveillance strategies represent an emerging topic of discussion. In comparison with previous years, this year we have found few truly original and innovative studies. Rather, the attention of the researchers seems to be focused on confirming and consolidating acquired data, in particular:<p class="ab...
0 shares

ey0018.9-1 | Cancer treatment and the risk of second neoplasia | ESPEYB18

9.1. Risk factors of subsequent central nervous system tumors after childhood and adolescent cancers: findings from the french childhood cancer survivor study

NMY Journy , WS Zrafi , S Bolle , B Fresneau , C Alapetite , RS Allodji , D Berchery , N Haddy , I Kobayashi , M Labbe , H Pacquement , C Pluchart , B Schwartz , V Souchard , C Thomas-Teinturier , C Veres , G Vu-Bezin , I Diallo , F de Vathaire

Cancer Epidemiol Biomarkers Prev. 2021; 30: 133–141. https://pubmed.ncbi.nlm.nih.gov/33033142/This retrospective study of 152 patients and 604 matched-controls within the FCCSS (French Childhood Cancer Survivor Study) cohort aimed to identify clinical and therapeutic factors associated with long-term risk of subsequent primary neoplasm (SPN) in the central nervous system (CNS), occurri...
0 shares

ey0018.9-2 | Cancer treatment and the risk of second neoplasia | ESPEYB18

9.2. Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer

C Thomas-Teinturier , I Oliver-Petit , H Pacquement , B Fresneau , RS Allodji , C Veres , S Bolle , D Berchery , CHaddy N Demoor-Goldschmidt , I Diallo , F. cecile.teinturier@aphp.fr de Vathaire

Eur J Endocrinol. 2020; 183: 471–480. https://pubmed.ncbi.nlm.nih.gov/32738133/This cohort and nested case–control study analyzed the impact of growth hormone (GH) treatment on the risk of second neoplasm (SN) in a French cohort of 2852 childhood cancer survivors (CCS) treated before 1986. In total, 126 (64.3%) survivors who received GH had been treated for a brain tumor, 22 (11.2...
0 shares

ey0018.9-3 | Childhood cancer and thyroid disease | ESPEYB18

9.3. Presentation and outcome of subsequent thyroid cancer among childhood cancer survivors compared to sporadic thyroid cancer: a matched national study

SC Clement , CA Lebbink , MS Klein Hesselink , JC Teepen , TP Links , CM Ronckers , HM van Santen

Eur J Endocrinol. 2020; 183: 169–180. https://pubmed.ncbi.nlm.nih.gov/32449692/This retrospective study analyzed subsequent differentiated thyroid cancer (DTC) in in a group of CCS (n=31) matched with patients affected by sporadic DTC (n=93) to compare clinical presentation and outcomes. CCS with subsequent DTC were identified by two source populations: the DCOG-LATER cohort o...
0 shares

ey0018.9-4 | Thyroid disorders in inflammatory bowel diseases | ESPEYB18

9.4. Infliximab therapy could decrease the risk of the development of thyroid disorders in pediatric patients with Crohn's Disease

A Furtak , AM Wedrychowicz , M Sladek , A Wedrychowicz , K Fyderek , J Starzyk

Front Endocrinol (Lausanne). 2020; 11: 558897. https://pubmed.ncbi.nlm.nih.gov/33042019/This patient cohort study evaluated the prevalence of autoimmune thyroid diseases (AITDs), defined as decreased thyroid echogenicity in 61 children with Crohn’s disease, 25 infliximab (IFX)-naïve (control group) and 36 IFX-treated patients (mean duration of IFX therapy 13.9±16.6 months). T...
0 shares

ey0018.9-5 | Surveillance strategies of endocrine complications | ESPEYB18

9.5. Beyond premature ovarian Insufficiency: staging reproductive aging in adolescent and young adult cancer survivors.

ACO Medica , BW Whitcomb , K Shliakhsitsava , AC Dietz , K Pinson , C Lam , SAD Romero , P Sluss , MD Sammel , HI Su

J Clin Endocrinol Metab. 2021;106: e1002–e1013. https://pubmed.ncbi.nlm.nih.gov/33141175/This cross-sectional study applied a commonly used system to classify reproductive aging (Stages of Reproductive Aging Workshop +10 or ‘STRAW +10’) to 338 adolescents and young adult (AYA) cancer survivors (1). The study aimed to evaluate if STRAW +10 correctly identifies premature ovaria...
0 shares

ey0018.9-6 | Surveillance strategies of endocrine complications | ESPEYB18

9.6. Female reproductive function after treatment of childhood acute lymphoblastic leukemia

R Roshandel , M van Dijk , A Overbeek , G Kaspers , C Lambalk , C Beerendonk , D Bresters , M van der Heiden-van der Loo , M van den Heuvel-Eibrink , L Kremer , J Loonen , H van der Pal , C Ronckers , W Tissing , B Versluys , F van Leeuwen , M van den Berg , E van Dulmen-den Broeder

Pediatr Blood Cancer. 2021; 68: e28894. https://pubmed.ncbi.nlm.nih.gov/33459500/This cross-sectional observational study examined reproductive function in a nationwide cohort of female childhood acute lymphoblastic leukemia (ALL) survivors.Self-reported reproductive characteristics (age at menarche, virginity status, desire for children, pregnancy rates, and adverse ...
0 shares

ey0018.9-7 | Surveillance strategies of endocrine complications | ESPEYB18

9.7. Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations.

A Cattoni , F Parissone , I Porcari , S Molinari , N Masera , M Franchi , S Cesaro , R Gaudino , P Passoni , A. alessandro.cattoni@unimib.it Balduzzi

Blood Rev. 2021; 45: 100730. https://pubmed.ncbi.nlm.nih.gov/32654893/This practical treatment protocol was developed by an experienced multidisciplinary team following a critical and updated systematic review of the literature.Hypogonadism is a common finding after antineoplastic treatment. It can either result from a primary gonadal disorder (due to pelvic irradiati...
0 shares

ey0018.9-8 | Genetic susceptibility to treatment-related gonadotoxicity | ESPEYB18

9.8. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

ALF van der Kooi , M van Dijk , L Broer , MH van den Berg , JSE Laven , FE van Leeuwen , CB Lambalk , A Overbeek , JJ Loonen , HJ van der Pal , WJ Tissing , B Versluys , D Bresters , CCM Beerendonk , CR Ronckers , M van der Heiden-van der Loo , GL Kaspers , ACH de Vries , LL Robison , MM Hudson , W Chemaitilly , J Byrne , C Berger , E Clemens , U Dirksen , J Falck Winther , SD Fossa , D Grabow , R Haupt , M Kaiser , T Kepak , J Kruseova , D Modan-Moses , SMF Pluijm , C Spix , O Zolk , P Kaatsch , JH Krijthe , LC Kremer , Y Yasui , RJ Brooke , AG Uitterlinden , M van den Heuvel-Eibrink , E Mvan Dulmen-den Broeder

Hum Reprod. 2021; 36: 1120–1133. https://pubmed.ncbi.nlm.nih.gov/33582778/This multi-centre retrospective cohort study identifies that common genetic variants in DNA repair genes modify the damage induced by alkylating agents on ovarian function, as assessed by low AMH levels.Alkylating agents are known to induce apoptosis of cancer cells by damaging DNA replicat...
0 shares

ey0018.9-9 | Reproductive outcomes in childhood cancer survivors | ESPEYB18

9.9. Risk of induced abortions in childhood cancer survivors

JM Melin , VI Seppanen , TM Ylostalo , NK Malila , JM Pitkaniemi , M Gissler , LS Madanat-Harjuoja

Cancer. 2021; 127: 1439–1447. https://pubmed.ncbi.nlm.nih.gov/33491215/This nationwide, Finnish registry-based study identified a lower likelihood of primary pregnancy (relative risk =0.72; 95% CI, 0.64–0.80) in 1357 childhood cancer survivors (CCS) diagnosed in 1971-2012 and 6658 age-matched general population controls. However the risk of induced abortion was similar in both gro...
0 shares

Published by BioScientifica

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more